Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

the treatment of cancer.  VAL-083 has been assessed in multiple clinical studies sponsored by the National Cancer Institute (NCI) in the United States as a treatment against various cancers including lung, brain, cervical, ovarian tumors and leukemia.  Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.  VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer.

DelMar is currently conducting a Phase I/II clinical trial with VAL-083 as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  In April 2012, DelMar presented data at the American Association of Cancer Research (AACR website:  http://www.aacr.org) annual meeting demonstrating that VAL-083 maintains activity in tumors resistant to the current front-line GBM therapy, Temodar®.  In November 2012, DelMar presented interim data from the ongoing GBM clinical trial at the Annual Meeting of the Society for NeuroOncology (SNO website:  http://www.soc-neuro-onc.org) demonstrating that VAL-083 can shrink or halt the growth of tumors in brain cancer patients who have failed other approved treatments.  Currently, there is no approved therapy for these patients. 

In addition to the Company's clinical development activities in the United States, DelMar has obtained exclusive commercial rights to VAL-083 in China.  In October 2012, DelMar announced a collaboration agreement with the only manufacturer presently licensed by the Chinese State Food and Drug Administration (SFDA) to produce VAL-083 for the China market.  This agreement provides DelMar with exclusive commercial right
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... FL (PRWEB) November 14, 2014 ... scientifically validated physical activity and sleep measurement platform ... improved subject experience along with multiple new channels ... and secondary accelerometer. Equipped with Bluetooth Smart technology, ... capture and mobile data uploads to ActiGraph’s cloud-based ...
(Date:11/15/2014)... The "Operating Room Management Market ... Application (Perioperative, Preoperative, operating room Scheduling), by Component ... Global Forecast to 2019.” defines and segments the ... forecast of value by product, such as data ... the value and volumes of operating room management ...
(Date:11/15/2014)... LONDON , Nov. 14, 2014 Algenol Biofuels ... 6th at the Oceanographic Museum of Monaco ... CleanEquity Monaco is an annual invitation-only event hosted by ... investment bank. Other partners and sponsors include ... Foundation, Covington & Burling, Cranfield University, PR Newswire, the Monte-Carlo ...
(Date:11/12/2014)... The “Pen Needles Market by by Needle Length ... Growth Hormones, Glucagon-like peptide) & by Type (Standard and ... and studies the major market drivers, threats, opportunities, and ... 51 figures spread through 185 pages and in-depth TOC ... by Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, and ...
Breaking Biology Technology:ActiGraph Launches GT9X Link Activity Monitor 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Algenol Biofuels Selected to Present at CleanEquity Monaco 2015 2Pen Needles Market worth $2,105 Million by 2019 - New Report by MarketsandMarkets 2Pen Needles Market worth $2,105 Million by 2019 - New Report by MarketsandMarkets 3Pen Needles Market worth $2,105 Million by 2019 - New Report by MarketsandMarkets 4
... , , , , , 7.6.4 ... increment, which can be programmed as desired with every temperature , command, enables ... each cycle. , , With Long PCR, ... extension of the , elongation. , , ...
... , , , , There is ... applied to all PCR amplifications. For example, , depending on ... of the PCRs can differ from each other. Finding the optimal or the , ... , and efficient amplification of a specific target. , ...
... , , , , , ... DNA fragment using the PCR* are an everyday occurrence in the lab. For ... PCR reaction, which hinder, , or even prevent, further ... unequivocal assessment of the PCR result. In such cases, PCR , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
(Date:11/7/2014)... SPRINGS, Florida , November 6, 2014 ... secure authentication for better mobile security revolutionizing online transactions.  Companies ... ), Alibaba Holdings Ltd. (NYSE: BABA ), Google ... MSFT ), eBay Inc. (NASDAQ: EBAY ) ... NXTD and NXTDW), a biometric authentication company ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... ANGELES, CA) -- The Disability Rights Legal Center (DRLC), ... rights of people with disabilities, has recognized Ossur, a ... orthopaedic products and services, with the Charles D. Siegal ... Prosthetics for Ossur Americas, accepted the award on Thursday ...
... Although its been over a decade since endothelial progenitor ... repairing and replacing the cells that line blood vessels, ... now being studied as biomarkers to assess the risk ... vascular regeneration. Researchers from the Herman ...
... Researchers at the University of North Carolina at Chapel Hill ... variant of the SARS coronavirus (CoV) that caused the SARS ... synthesizing the virus is a major step forward in their ... of SARS virus that might affect humans in the future. ...
Cached Biology News:Disability Rights Legal Center honors Ossur 2Understanding how oxidative stress impairs endothelial progenitor cell function 2Researchers recreate SARS virus, open door for potential defenses against future strains 2
... numbers of samples may be carried out using ... minimum operator attention. System control and data ... CE 4900. The elegant, powerful and very ... and Windows 98 and 2000., The supplied automatic ...
... CE 4100 high pressure dual piston pump and ... flexibility and utra low drift. The ... array detection and provides superior stability. ... development and for monitoring to the highest of ...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
Biology Products: